Personalized cell therapy has become a growing option for treatment of cancer and many other ailments. See MoreUsing engineered T cells that express chimeric antigen receptors or modified T cell receptors are becoming pivotal new approaches for targeting cancer cells.
The process of manufacturing genetically-modified T cells for cancer therapies or other applications may initially require the isolation of T cells or T cell subsets from
Leukopaks
or
whole blood samples
. STEMCELL Technologies provides fast, easy and column-free immunomagnetic
or immunodensity
cell separation platforms for the isolation of highly purified T cells in as little as 8 minutes. The purified cells are immediately ready for T cell activation and expansion, the next steps in the T cell engineering workflow.
From sourcing your starting sample to downstream T cell analysis, explore our complete portfolio of products to support your human T cell research workflow.
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not
share your email address with third parties. StemCell Technologies Inc. will use your email address to
confirm your identity and send you newsletters, transaction-related emails, promotional and customer
service emails in accordance with our privacy policy. You can change
your email preferences at any time.